Practice-Changing Advances in Immuno-Oncology for Non-Small-Cell Lung Cancer

Download All
Get up to date on the latest advances in immunotherapy for the management of advanced NSCLC with this educational program featuring an on-demand webcast and downloadable slidesets from a live CCO webinar where experts discuss the latest clinical data in the context of a series of patient cases.
person default
Mary Jo Fidler, MD
person default
Scott Gettinger, MD

On-Demand Webcast

Watch this on-demand webcast of a live CCO webinar where clinical experts discuss the latest advances in immunotherapy for the management of NSCLC, including discussion of patient cases across disease settings, integration of new data from ASCO 2021, and optimization of therapeutic benefit through management of cancer cachexia syndrome and immune-related adverse events.

person default Mary Jo Fidler, MD person default Scott Gettinger, MD Physicians: maximum of 1.5 AMA PRA Category 1 Credits Released: July 15, 2021 Expired: July 14, 2022

Downloadable Slidesets

Download these slides from a live CCO Webinar for a case-based overview of the optimal use of immunotherapy for the treatment of advanced or metastatic NSCLC, including first-line therapy decisions across the spectrum of PD-L1 expression levels and what to do after acquired resistance to checkpoint inhibition.

person default Scott Gettinger, MD Released: June 24, 2021

Download these slides from a live CCO Webinar for an overview of the evolving immunotherapy landscape for early-stage NSCLC along with coverage on how cachexia, immune-related adverse events, and disparities in care impact outcomes for patients with NSCLC receiving checkpoint inhibitor therapy.

person default Mary Jo Fidler, MD Released: June 24, 2021

Download this short summary slideset of key takeaways from a live CCO Webinar on immunotherapy for the treatment of patients with NSCLC, including new advances in early-stage disease, updated data for unresectable stage III and advanced disease, and clinical factors influencing response to immune checkpoint inhibitor therapy.

person default Mary Jo Fidler, MD person default Scott Gettinger, MD Released: July 2, 2021
Provided by Clinical Care Options, LLC

Contact Clinical Care Options

For customer support please email: customersupport@clinicaloptions.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Educational grant provided by:
Helsinn Healthcare SA
Regeneron Pharmaceuticals, Inc.
Sanofi Genzyme

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue